Abstract
BACKGROUND. Vinca alkaloids have proved active against a number of pediatric malignancies. The aim of this study was to assess the feasibility and effectiveness of using vinorelbine in previously treated pediatric patients with advanced sarcomas. METHODS. From September 1998 to August 2001, 33 previously treated patients with progressive sarcoma were treated: 13 had rhabdomyosarcomas, 5 had other soft tissue sarcomas, 9 had Ewing sarcomas, and 6 had osteosarcomas. Vinorelbine was given intravenously on Days 1 and 8 of a 21-day treatment cycle. Four patients with uncontrolled pain or central nervous system invasion received concurrent radiotherapy and were only evaluated for toxicity. RESULTS. One hundred seventy-eight treatment cycles were administered (median of four per patient, range 1-20). Grade 3 to 4 neutropenia occurred in 63% of patients, Grade 3 anemia in 9%, and Grade 3 thrombocytopenia in 3%. Nonhematological toxicity was mild or moderate, i.e., always lower than Grade 3, with the exception of one child who experienced paralytic ileus. Twenty-eight patients were assessable for response. Eight patients had a partial response, one patient had a minor response, and nine patients had stable disease. Objective responses were observed in 6 of 12 patients with rhadbomyosarcomas (five of six of the alveolar subtype), in one of five patients with osteosarcomas, and in one of seven patients with Ewing sarcomas. The median duration of response was 10 months (range, 3+ to 20). CONCLUSIONS. Vinorelbine has a favorable toxicity profile with evidence of biological activity in already heavily treated pediatric patients with sarcomas. In particular, the objective response rate obtained for patients with alveolar rhabdomyosarcoma seems very promising. Due to the few cases considered here, further Phase II studies are needed to establish a potential role of vinorelbine in the treatment of these tumors.
| Original language | English |
|---|---|
| Pages (from-to) | 3263-3268 |
| Number of pages | 6 |
| Journal | Cancer |
| Volume | 94 |
| Issue number | 12 |
| DOIs | |
| Publication status | Published - Jun 15 2002 |
Fingerprint
Keywords
- New drugs
- Pediatric sarcoma
- Rhabdomyosarcoma
- Vinorelbine
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Vinorelbine in previously treated advanced childhood sarcomas : Evidence of activity in rhadbomyosarcoma. / Casanova, Michela; Ferrari, Andrea; Spreafico, Filippo; Terenziani, Monica; Massimino, Maura; Luksch, Roberto; Cefalo, Graziella; Polastri, Daniela; Marcon, Ilaria; Bellani, Franca Fossati.
In: Cancer, Vol. 94, No. 12, 15.06.2002, p. 3263-3268.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Vinorelbine in previously treated advanced childhood sarcomas
T2 - Evidence of activity in rhadbomyosarcoma
AU - Casanova, Michela
AU - Ferrari, Andrea
AU - Spreafico, Filippo
AU - Terenziani, Monica
AU - Massimino, Maura
AU - Luksch, Roberto
AU - Cefalo, Graziella
AU - Polastri, Daniela
AU - Marcon, Ilaria
AU - Bellani, Franca Fossati
PY - 2002/6/15
Y1 - 2002/6/15
N2 - BACKGROUND. Vinca alkaloids have proved active against a number of pediatric malignancies. The aim of this study was to assess the feasibility and effectiveness of using vinorelbine in previously treated pediatric patients with advanced sarcomas. METHODS. From September 1998 to August 2001, 33 previously treated patients with progressive sarcoma were treated: 13 had rhabdomyosarcomas, 5 had other soft tissue sarcomas, 9 had Ewing sarcomas, and 6 had osteosarcomas. Vinorelbine was given intravenously on Days 1 and 8 of a 21-day treatment cycle. Four patients with uncontrolled pain or central nervous system invasion received concurrent radiotherapy and were only evaluated for toxicity. RESULTS. One hundred seventy-eight treatment cycles were administered (median of four per patient, range 1-20). Grade 3 to 4 neutropenia occurred in 63% of patients, Grade 3 anemia in 9%, and Grade 3 thrombocytopenia in 3%. Nonhematological toxicity was mild or moderate, i.e., always lower than Grade 3, with the exception of one child who experienced paralytic ileus. Twenty-eight patients were assessable for response. Eight patients had a partial response, one patient had a minor response, and nine patients had stable disease. Objective responses were observed in 6 of 12 patients with rhadbomyosarcomas (five of six of the alveolar subtype), in one of five patients with osteosarcomas, and in one of seven patients with Ewing sarcomas. The median duration of response was 10 months (range, 3+ to 20). CONCLUSIONS. Vinorelbine has a favorable toxicity profile with evidence of biological activity in already heavily treated pediatric patients with sarcomas. In particular, the objective response rate obtained for patients with alveolar rhabdomyosarcoma seems very promising. Due to the few cases considered here, further Phase II studies are needed to establish a potential role of vinorelbine in the treatment of these tumors.
AB - BACKGROUND. Vinca alkaloids have proved active against a number of pediatric malignancies. The aim of this study was to assess the feasibility and effectiveness of using vinorelbine in previously treated pediatric patients with advanced sarcomas. METHODS. From September 1998 to August 2001, 33 previously treated patients with progressive sarcoma were treated: 13 had rhabdomyosarcomas, 5 had other soft tissue sarcomas, 9 had Ewing sarcomas, and 6 had osteosarcomas. Vinorelbine was given intravenously on Days 1 and 8 of a 21-day treatment cycle. Four patients with uncontrolled pain or central nervous system invasion received concurrent radiotherapy and were only evaluated for toxicity. RESULTS. One hundred seventy-eight treatment cycles were administered (median of four per patient, range 1-20). Grade 3 to 4 neutropenia occurred in 63% of patients, Grade 3 anemia in 9%, and Grade 3 thrombocytopenia in 3%. Nonhematological toxicity was mild or moderate, i.e., always lower than Grade 3, with the exception of one child who experienced paralytic ileus. Twenty-eight patients were assessable for response. Eight patients had a partial response, one patient had a minor response, and nine patients had stable disease. Objective responses were observed in 6 of 12 patients with rhadbomyosarcomas (five of six of the alveolar subtype), in one of five patients with osteosarcomas, and in one of seven patients with Ewing sarcomas. The median duration of response was 10 months (range, 3+ to 20). CONCLUSIONS. Vinorelbine has a favorable toxicity profile with evidence of biological activity in already heavily treated pediatric patients with sarcomas. In particular, the objective response rate obtained for patients with alveolar rhabdomyosarcoma seems very promising. Due to the few cases considered here, further Phase II studies are needed to establish a potential role of vinorelbine in the treatment of these tumors.
KW - New drugs
KW - Pediatric sarcoma
KW - Rhabdomyosarcoma
KW - Vinorelbine
UR - http://www.scopus.com/inward/record.url?scp=0037096950&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037096950&partnerID=8YFLogxK
U2 - 10.1002/cncr.10600
DO - 10.1002/cncr.10600
M3 - Article
C2 - 12115359
AN - SCOPUS:0037096950
VL - 94
SP - 3263
EP - 3268
JO - Cancer
JF - Cancer
SN - 0008-543X
IS - 12
ER -